Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 355

The DOI matches its Crossref record; 172 of the 172 references it cites were found in a registry or an index.

New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes

Open access
Senni, M., Paulus, W. J., Gavazzi, A., Fraser, A. G., Diez, J., Solomon, S. D., Smiseth, O. A., Guazzi, M., Lam, C. S. P., Maggioni, A. P., Tschope, C., Metra, M., Hummel, S. L., Edelmann, F., Ambrosio, G., Stewart Coats, A. J., Filippatos, G. S., Gheorghiade, M., Anker, S. D., Levy, D., Pfeffer, M. A., Stough, W. G., Pieske, B. M.·2014·European Heart Journal

Abstract

The management of heart failure with reduced ejection fraction (HF-REF) has improved significantly over the last two decades. In contrast, little or no progress has been made in identifying evidence-based, effective treatments for heart failure with preserved ejection fraction (HF-PEF). Despite the high prevalence, mortality, and cost of HF-PEF, large phase III international clinical trials investigating interventions to improve outcomes in HF-PEF have yielded disappointing results. Therefore, treatment of HF-PEF remains largely empiric, and almost no acknowledged standards exist. There is no single explanation for the negative results of past HF-PEF trials. Potential contributors include an incomplete understanding of HF-PEF pathophysiology, the heterogeneity of the patient population, inadequate diagnostic criteria, recruitment of patients without true heart failure or at early stages of the syndrome, poor matching of therapeutic mechanisms and primary pathophysiological processes, suboptimal study designs, or inadequate statistical power. Many novel agents are in various stages of research and development for potential use in patients with HF-PEF. To maximize the likelihood of identifying effective therapeutics for HF-PEF, lessons learned from the past decade of research should be applied to the design, conduct, and interpretation of future trials. This paper represents a synthesis of a workshop held in Bergamo, Italy, and it examines new and emerging therapies in the context of specific, targeted HF-PEF phenotypes where positive clinical benefit may be detected in clinical trials. Specific considerations related to patient and endpoint selection for future clinical trials design are also discussed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehu204

Cites

172 of 172 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 172 references

Cited by

See all 355

Metadata

Authors
Senni, M., Paulus, W. J., Gavazzi, A., Fraser, A. G., Diez, J., Solomon, S. D., Smiseth, O. A., Guazzi, M., Lam, C. S. P., Maggioni, A. P., Tschope, C., Metra, M., Hummel, S. L., Edelmann, F., Ambrosio, G., Stewart Coats, A. J., Filippatos, G. S., Gheorghiade, M., Anker, S. D., Levy, D., Pfeffer, M. A., Stough, W. G., & Pieske, B. M.
Venue
European Heart Journal
Published
2014-08-07
Volume
35
Issue
40
Pages
2797-2815
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2122465146
Cited by
355
References
172
FWCI
29.27
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. https://app.cochat.ai/papers/10.1093/eurheartj/ehu204
The paper
Senni, M., Paulus, W. J., Gavazzi, A., Fraser, A. G., Diez, J., Solomon, S. D., Smiseth, O. A., Guazzi, M., Lam, C. S. P., Maggioni, A. P., Tschope, C., Metra, M., Hummel, S. L., Edelmann, F., Ambrosio, G., Stewart Coats, A. J., Filippatos, G. S., Gheorghiade, M., Anker, S. D., . . . Pieske, B. M. (2014). New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. European Heart Journal. https://doi.org/10.1093/eurheartj/ehu204

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.